open access

Vol 67, No 4 (2016)
Original papers
Published online: 2016-07-05
Submitted: 2015-10-17
Accepted: 2016-02-05
Get Citation

Determination of advanced glycation end-products and antibodies against them (anti-CML and anti-CEL) in the serum of Graves’ orbitopathy patients before and after methylprednisolone treatment

Janusz Strzelczyk, Magdalena Szumska, Aleksandra Damasiewicz-Bodzek, Anna Krywult, Michał Długaszek, Justyna Czubilińska, Kaja Gawlik, Konrad Synowiec, Krystyna Tyrpień-Golder, Karolina Poczkaj, Beata Kos-Kudła
DOI: 10.5603/EP.a2016.0047
·
Endokrynologia Polska 2016;67(4):383-389.

open access

Vol 67, No 4 (2016)
Original papers
Published online: 2016-07-05
Submitted: 2015-10-17
Accepted: 2016-02-05

Abstract

Introduction: The glycation process is a non-enzymatic modification of proteins occurring due to the reactions of reductive carbohydrates. The glycated residues lose their biological functions, and their removal process is ineffective. They accumulate, and as a result they cause an immunological response. The aim of this study was a determination of the concentrations of advanced glycation end-products and antibodies against carboxymethyl lysine (anti-CML) and carboxyethyl lysine (anti-CEL) in the sera of Graves’ orbitopathy patients.

Material and methods: The study group were patients from the Division of Endocrinology of the Medical University of Silesia (n = 25) suffering from Graves’ orbitopathy. The concentration of AGE-peptides using flow spectrofluorimetry method, and anti-CML and anti-CEL IgG antibodies using immunoenzymatic technique (ELISA), were measured in patients sera before and after methylprednisolone treatment.

Results: In sera of the study group the concentrations of AGE-peptides and anti-CML were significantly lower before and after treatment in comparison to the control group (p < 0.05). Mean values of anti-CEL concentrations were comparable (at both phases of treatment) with the value observed in the control group. After treatment the concentrations of AGE-peptides and anti-CEL significantly decreased (p < 0.05); however, the concentration of anti-CML was also lower but the observed change was not significant (p > 0.05).

Conclusions: In the course of Graves’ orbitopathy the glycation process is disturbed. The treatment modifies significantly the process by lowering the concentration of advanced glycation end-products and suppressing the immune response to them. (Endokrynol Pol 2016; 67 (4): 383–389)

Abstract

Introduction: The glycation process is a non-enzymatic modification of proteins occurring due to the reactions of reductive carbohydrates. The glycated residues lose their biological functions, and their removal process is ineffective. They accumulate, and as a result they cause an immunological response. The aim of this study was a determination of the concentrations of advanced glycation end-products and antibodies against carboxymethyl lysine (anti-CML) and carboxyethyl lysine (anti-CEL) in the sera of Graves’ orbitopathy patients.

Material and methods: The study group were patients from the Division of Endocrinology of the Medical University of Silesia (n = 25) suffering from Graves’ orbitopathy. The concentration of AGE-peptides using flow spectrofluorimetry method, and anti-CML and anti-CEL IgG antibodies using immunoenzymatic technique (ELISA), were measured in patients sera before and after methylprednisolone treatment.

Results: In sera of the study group the concentrations of AGE-peptides and anti-CML were significantly lower before and after treatment in comparison to the control group (p < 0.05). Mean values of anti-CEL concentrations were comparable (at both phases of treatment) with the value observed in the control group. After treatment the concentrations of AGE-peptides and anti-CEL significantly decreased (p < 0.05); however, the concentration of anti-CML was also lower but the observed change was not significant (p > 0.05).

Conclusions: In the course of Graves’ orbitopathy the glycation process is disturbed. The treatment modifies significantly the process by lowering the concentration of advanced glycation end-products and suppressing the immune response to them. (Endokrynol Pol 2016; 67 (4): 383–389)

Get Citation

Keywords

Graves’ orbitiopathy; methylprednisolone treatment; anti-CML; anti-CEL

About this article
Title

Determination of advanced glycation end-products and antibodies against them (anti-CML and anti-CEL) in the serum of Graves’ orbitopathy patients before and after methylprednisolone treatment

Journal

Endokrynologia Polska

Issue

Vol 67, No 4 (2016)

Pages

383-389

Published online

2016-07-05

DOI

10.5603/EP.a2016.0047

Bibliographic record

Endokrynologia Polska 2016;67(4):383-389.

Keywords

Graves’ orbitiopathy
methylprednisolone treatment
anti-CML
anti-CEL

Authors

Janusz Strzelczyk
Magdalena Szumska
Aleksandra Damasiewicz-Bodzek
Anna Krywult
Michał Długaszek
Justyna Czubilińska
Kaja Gawlik
Konrad Synowiec
Krystyna Tyrpień-Golder
Karolina Poczkaj
Beata Kos-Kudła

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl